One study examined the expression levels of HIF-1α protein in 153 patients with DLBCL treated sequentially with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab-CHOP (R-CHOP), and the results indicated that HIF-1α is correlated with the outcomes of DLBCL patients.130. The gene discussed is HIF1A; the disease is diffuse large B-cell lymphoma.